Medtronic Secures FDA, CE Marks for Advanced Cardiac Mapping and Ablation Software
Event summary
- Medtronic received FDA clearance and CE Mark for Affera™ Prism-2 Mapping Software on September 30, 2026.
- CE Mark obtained for PulseSelect ProxBox™ Adapter with Proximity Indicator software.
- Affera Prism-2 Software enhances cardiac mapping with Beat Matching, Pace Tagging, and improved pacing stimulator.
- PulseSelect ProxBox™ Adapter provides real-time tissue proximity feedback for safer ablation procedures.
The big picture
Medtronic's regulatory wins position it to capture more of the growing cardiac ablation market, where software-driven precision is becoming a key differentiator. The enhancements align with industry trends toward reduced fluoroscopy use and more integrated electrophysiology platforms. With the PulseSelect system already in 60+ countries, the proximity feedback feature could further solidify Medtronic's leadership in pulsed field ablation technology.
What we're watching
- Adoption Pace
- How quickly hospitals and electrophysiologists will integrate the new software into existing workflows.
- Competitive Response
- Whether competitors like Boston Scientific or Abbott will accelerate their own software enhancements.
- Revenue Impact
- The extent to which these software upgrades drive procedural volume growth for Medtronic's ablation platforms.
